At what enterprise value was SEBIA acquired in 2025?

During the acquisition of SEBIA by WARBURG PINCUS in 2025, the transaction's Enterprise Value is estimated to be in the range of 3b - 100b EUR.

What was the EV/EBITDA of SEBIA when it was acquired by WARBURG PINCUS?

The estimated EV/EBITDA multiple for SEBIA is in the range of Above 20x.

When was SEBIA acquired by WARBURG PINCUS?

SEBIA was acquired by WARBURG PINCUS in 2025.

What was the revenue of SEBIA at the time of the deal?

The revenue of SEBIA at the time of the deal is estimated to be in the range of 450M - 900M EUR.

What was the EBITDA of SEBIA during the acquisition?

SEBIA's EBITDA is estimated to be in the range of 150M - 250M EUR.

How is the data for the SEBIA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the SEBIA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/sebia-se-valorise-plus-de-5-mdeur-aupres-de-warburg-pincus-2192808

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaSEBIA

08/2025

SEBIA acquired by WARBURG PINCUS

FRANCE Life Sciences / Medical Devices / Diagnostic Equipment EV 3b - 100b EUR

Context

The French medical diagnostics giant Sebia welcomes a new heavyweight investor, Warburg Pincus, into its capital. This transaction, valuing the company at over EUR5 billion, sees the partial exit of minority shareholders CDPQ and ICG. The current majority owners, CVC Capital Partners and Tethys Invest (the Bettencourt-Meyers family office), retain a significant stake and will continue to back the company alongside Warburg Pincus. This new consortium aims to support Sebia's expansion in the US and Asian markets and fund potential acquisitions in the IVD space.

It is worth noting that the fund Cvc took control of Sebia through an LBO in 2017.

SEBIA, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

A global leader in in-vitro diagnostics (IVD), specializing in clinical electrophoresis technology. Founded in 1967, Sebia provides automated equipment and reagents used by medical laboratories worldwide to screen and monitor diseases such as multiple myeloma, metabolic disorders (diabetes), and hemoglobinopathies. The company generates over 90% of its sales internationally and has a direct presence in 15 countries.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Other operations with SEBIA

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
10/2017	CVC	SEBIA	FRANCE	Diagnostic Equipment

REFERENCES

Valuation range: EV 3b - 100b EUR

Revenue range: 450M - 900M EUR

EBITDA range: 150M - 250M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SEBIA by WARBURG PINCUS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: sebia

Acquirer: warburg pincus